Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Evolution of IT and Healthcare…Where do we go from here?

Healthcare leaders are facing the challenge of fragmented data systems, which impacts both their operations and patients' ability to access medical records. During a podcast episode, Brian Urban and Dr. Steven Lane discuss the importance of interoperability, the challenges of patient engagement, and the potential of a user-friendly app ecosystem in healthcare. The conversation highlights the need for secure communication channels and innovative, patient-centered technological solutions.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Brian Urban ·
Share
The Evolution of IT and Healthcare…Where do we go from here?

Key takeaways

01

Interoperability is essential for seamless data exchange and coordinated, patient-centered care.

02

Patients face challenges with engagement due to disparate technology systems and overwhelming tools.

03

Providing secure channels for communication between patients and healthcare providers enhances engagement and health outcomes.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

In this episode of the Rethink Healthcare podcast, host Brian Urban is joined by Dr. Steven Lane, Chief Medical Officer of Health Gorilla.

Health Gorilla is revolutionizing interoperability within the healthcare ecosystem by enabling seamless data exchange and faster access to information.

Urban and Lane discuss:

  1. the importance of interoperability and data exchange in healthcare, as well as the need for patients to have access to their own health information.
  2. Patient engagement challenges due to various factors such as technological limitations, multiple health IT systems, and the need for flexible solutions that cater to different individuals’ needs.
  3. Creating an app ecosystem that allows patients to choose the tools they prefer for interacting with their healthcare team and streamlining workflows such as messaging, refill requests, result check-ups, bill payment, and more.

Dr. Lane emphasizes the importance of interoperability in today’s healthcare landscape, where patients receive care from multiple providers using different EMR systems. Seamless data exchange is crucial for delivering coordinated and patient-centered care.

Seamless data exchange is crucial for delivering coordinated and patient-centered care.

He also highlights the significance of patient engagement in healthcare delivery. Patients are increasingly aware of their treatment paths and seek to be actively involved in their care decisions. However, challenges such as disparate technology systems, lack of awareness, and overwhelming patient engagement tools hamper effective communication between doctors and patients.

Dr. Lane believes that building a strong doctor-patient relationship based on trust is essential for fostering engagement. Providing patients with secure channels to communicate with their care team encourages active participation and enables better health outcomes. He acknowledges that patient portals have limitations but emphasizes that patients appreciate having a safe space to connect with their healthcare providers.

Patients appreciate having a safe space to connect with their healthcare providers.

Driven by this understanding, he continues to advocate for improved access to information through modern APIs and user-friendly applications. Dr. Lane’s journey exemplifies the transformative power of interoperability and patient engagement in healthcare delivery. By embracing new technologies and innovative solutions like those offered by Health Gorilla, the industry can create a future where healthcare is truly patient-centered.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Brian Urban
Brian UrbanDirector of Innovation & Emerging Markets

Brian Urban has a deep skill set in health promotion and product development for rare disease and senior populations with Large Health Plans and Specialty Pharmacy. Urban has served as a speaker on such topics for the Alzheimer’s Association, Obediah Cole Prostate Cancer Foundation, Cigna Corp and Utica University Institute for the study of integrative healthcare. Urban has received a Masters of Science in Exercise Physiology-Health Promotion, Masters of Business Administration in Market Development and is currently completing a Masters in Public Health at Dartmouth College. Urban is currently a research-fellow sponsored by a Robert Wood Johnson Grant supporting Utica University public health research in Upstate New York.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA named Corewell Health CFO Matthew E. Cox as its national chair effective June 1, 2026, while elevating revenue cycle and reimbursement leaders to its board, according to HFMA’s GlobeNewswire announcement. The association’s own coverage of CMS’s FY 2027 IPPS/LTCH PPS final rule summary and new Medicare cost-reporting requirements such as Worksheet S-12 indicates a compliance workload that is increasingly data- and documentation-heavy for hospital finance and reporting teams. In parallel, HFMA’s certification catalog, including the Certified Hospital Cost Report Specialist (CHCRS) and Certified Specialist Payment & Reimbursement (CSPR), points to how health systems are professionalizing the skill sets needed to operationalize reimbursement policy changes. For operators, the practical consequence shows up in staffing models, audit readiness, and the data plumbing needed to produce defensible cost reports and faster revenue cycle decisions.

  • 01HFMA’s board slate now visibly includes roles that control the work: a system CFO (Corewell Health) and a chief revenue officer overseeing $7 billion in patient revenue at Orlando Health, per GlobeNewswire. That’s a signal that cost reporting and revenue cycle execution are board-level concerns, not back-office chores.
  • 02Medicare cost reporting is moving toward more granular worksheets and documentation, and each new CMS reporting requirement becomes a data-integration project before it becomes a policy memo, per HFMA’s reporting on Worksheet S-12 and its FY 2027 IPPS/LTCH PPS coverage.
  • 03HFMA’s CHCRS, CRCR, and CSPR credentials provide a concrete way to benchmark internal capability: if cost report preparation, managed care contract terms, and prior auth workflows live in different teams, credentialing can reveal where handoffs are breaking down.

Sep 2, 2026

FDA QMSR ties supplier contracts to inspection prep

FDA QMSR ties supplier contracts to inspection prep

FDA’s Quality Management System Regulation (QMSR) took effect Feb. 2, 2026, incorporating ISO 13485:2016 into 21 CFR Part 820 and shifting inspections to a process-based model under Compliance Program 7382.850, according to MD+DI. That change is starting to show up outside the quality department: medical device OEMs are being pushed to spell out documentation, audit support, and change-control responsibilities in contract manufacturing agreements, as Medical Design and Outsourcing described. Two recent partnership moves, Ratio Therapeutics expanding radiopharmaceutical manufacturing with PharmaLogic in Idaho Falls and Menicon shifting U.S. Rose K manufacturing access to three partners after concluding a prior arrangement, illustrate how multi-party supply chains now need contract terms that map directly to integrated QMS evidence. The operational consequence is simple: under CP 7382.850, a complaint, supplier nonconformance, or process change can pull investigators across CAPA, risk management, purchasing, and design records in one thread, so contracts and quality records have to be built to travel together.

  • 01Under FDA CP 7382.850, inspection risk increasingly sits in the “handoffs” between complaint handling, CAPA, supplier controls, and the Risk Management File, so quality evidence has to be assembled end-to-end, not by department.
  • 02For OEMs outsourcing manufacturing, the most useful contract test in 2026 is whether each clause produces inspectable artifacts, who owns them, where they live, and how fast they can be produced during an audit.
  • 03Multi-partner manufacturing models, like Menicon’s three-partner Rose K availability and Ratio’s capacity expansion with PharmaLogic, raise the bar on configuration control, supplier risk classification, and change notification across sites.

Sep 2, 2026

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

The FDA’s interchangeable biosimilar pathway is moving from a one-off insulin milestone to a repeatable playbook for pharmacy-level substitution, with Wezlana (ustekinumab-auub) approved as interchangeable to Stelara in late 2023 and a first interchangeable biosimilar to golimumab reported in September 2026. Evidence from a JAMA Health Forum economic evaluation cited by Podiatry Today found that insulin glargine interchangeability in November 2021 was followed by an immediate jump of more than 47,000 prescriptions for Semglee and insulin glargine-yfgn, suggesting the designation itself can change dispensing behavior. For hospitals, health systems, and payers, the operational consequence shows up less in the FDA letter and more in formulary design, NDC-level claims logic, pharmacy notification requirements that vary by state, and the inventory and education workflows that make substitution predictable instead of chaotic.

  • 01Interchangeability is a workflow change, not a clinical debate. The systems that decide spend are NDC mapping, e-prescribe defaults, and pharmacy switch rules governed by state law.
  • 02The pipeline is widening beyond diabetes. Wezlana’s interchangeability to Stelara (Healthcare Purchasing News) and a newly reported interchangeable golimumab biosimilar (Journal of Healthcare Management/AJN via Ovid) signal more specialty and infusion-adjacent categories will face pharmacy-level substitution decisions.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

Brian Urban
Brian Urban

Director of Innovation & Emerging Markets

Brian Urban has a deep skill set in health promotion and product development for rare disease and senior populations with Large Health Plans and Specialty Pharmacy. Urban has served as a speaker on such topics for the Alzheimer’s Association, Obediah Cole Prostate Cancer Foundation, Cigna Corp and Utica University Institute for the study of integrative healthcare. Urban has received a Masters of Science in Exercise Physiology-Health Promotion, Masters of Business Administration in Market Development and is currently completing a Masters in Public Health at Dartmouth College. Urban is currently a research-fellow sponsored by a Robert Wood Johnson Grant supporting Utica University public health research in Upstate New York.

DS
Dr. Steven Lane

Chief Medical Officer

Health Gorilla

Dr. Steven Lane is the Chief Medical Officer at Health Gorilla, focusing on enhancing data interoperability in the healthcare sector. With a commitment to patient-centered care, he advocates for seamless information exchange and strong doctor-patient relationships.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512